Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin

Journal of Clinical Oncology

Volumn 17, Issue 10, 1999, Pages 3009-3016

  Thodtmann R ^a   Depenbrock, H ^a   Dumez, H ^a   Blatter, J ^a   Johnson, R D ^a   van Oosterom, A ^a   Hanauske, A R ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FOLIC ACID ANTAGONIST; PEMETREXED;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG CLEARANCE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SKIN TOXICITY; SOLID TUMOR; SQUAMOUS CELL CARCINOMA;

EID: 0344980120     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1999.17.10.3009     Document Type: Article

References (12)

1. Baldwin SW, Tse A, Taylor EC, et al: Structure features of 5,10-dideazatetrahydrofolate that determine inhibition of mammalian glycinamide ribonucleotide formyltransferase. Biochemistry J 30:1997-2006, 1991
2. Taylor EC, Kuhnt D, Shih C, et al: A dideazatetrahydrofolate analogue lacking a chiral center at C-6, N-[4-[2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl] benzoyl]-L-glutamic acid, is an inhibitor of thymidylate synthase. J Med Chem 35:4450-4454, 1992
3. Shih C, Chen VJ, Gossett LS, et al: LY231514. a pyrrolo[2,3-d]pyrimidine based antifolate that inhibits multiple folate requiring enzymes. Cancer Res 57:1116-1123, 1997
4. Allegra CJ: Antifolates, in Chabner BA, Collins JM (eds): Cancer Chemotherapy: Principles and Practice (vol 5). Philadelphia, PA, Lippincott, 1990, pp 110-153
5. Tonkinson JL, Marder P, Andis SL, et al: Cell cycle effects of antifolate antimetabolites: Implications for cytotoxicity and cytostasis. Cancer Chemother Pharmacol 39:521-531, 1997
6. Worzalla JF, Self TD, Theobald KS, et al: Effects of folic acid on toxicity and antitumor activity of LY231514 multi-targeted antifolate (MTA). Proc Am Assoc Cancer Res 38:478a, 1997 (abstr 3198)
7. Rinaldi DA, Burris HA, Dorr FA, et al: Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol 13:2842-2850, 1995
8. McDonald AC, Vasey PA, Adams L, et al: A Phase I and pharmacokinetic study of LY 231514, the multitargeted antifolate. Clin Cancer Res 4:605-610, 1998
9. Rinaldi DA, Burris HA, Dorr FA, et al: A phase I evaluation of LY231524, a novel multitarget antifolate, administered every 21 days. Proc Am Soc Clin Oncol 15:489a, 1996 (abstr 559)
10. Investigators Handbook: A Manual for Participants in Clinical Trials of Investigational Agents Sponsored by the Division of Cancer Treatment. Bethesda, MD, National Cancer Institute, 1996
11. th ASMS Conference on Mass Spectrometry and Allied Topics, Dallas, TX, June 13-18, 1999
12. Miller AB, Hoogstraten S, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981